First‐day step‐down to oral outpatient treatment versus continued standard treatment in children with cancer and low‐risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN study
- 23 January 2012
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 59 (3), 423-430
- https://doi.org/10.1002/pbc.24076
Abstract
The standard treatment of fever in chemotherapy‐induced neutropenia (FN) includes emergency hospitalization and empirical intravenous antimicrobial therapy. This study determined if first‐day step‐down to oral outpatient treatment is not inferior to continued standard regarding safety and efficacy in children with low‐risk FN. In a randomized controlled non‐blinded multicenter study, pediatric patients with FN after non‐myeloablative chemotherapy were reassessed after 8–22 hours of inpatient intravenous antimicrobial therapy. Low‐risk patients were randomized to first‐day step‐down to experimental (outpatient, oral amoxicillin plus ciprofloxacin) versus continued standard treatment. Exact non‐inferiority tests were used for safety (no serious medical complication; non‐inferiority margin of difference, 3.5%) and efficacy (resolution of infection without recurrence, no modification of antimicrobial therapy, no adverse event; 10%). In 93 (26%) of 355 potentially eligible FN episodes low‐risk criteria were fulfilled, and 62 were randomized, 28 to experimental (1 lost to follow‐up) and 34 to standard treatment. In intention‐to‐treat analyses, non‐inferiority was not proven for safety [27 of 27 (100%) vs. 33 of 34 (97%; 1 death) episodes; 95% upper confidence border, 6.7%; P = 0.11], but non‐inferiority was proven for efficacy [23 of 27 (85%) vs. 26 of 34 (76%) episodes; 95% upper confidence border, 9.4%; P = 0.045]. Per‐protocol analyses confirmed these results. In children with low‐risk FN, the efficacy of first‐day step‐down to oral antimicrobial therapy with amoxicillin and ciprofloxacin in an outpatient setting was non‐inferior to continued hospitalization and intravenous antimicrobial therapy. The safety of this procedure, however, was not assessable with sufficient power. Pediatr Blood Cancer 2012;59:423–430.Keywords
Funding Information
- Oncosuisse/Swiss Cancer League (OCS-01466-02-2004)
- Bayer AG
- GSK AG
This publication has 40 references indexed in Scilit:
- Health-related quality of life anticipated with different management strategies for paediatric febrile neutropaeniaBritish Journal of Cancer, 2011
- Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2011
- Systematic review and meta-analysis of the discriminatory performance of risk prediction rules in febrile neutropaenic episodes in children and young peopleEuropean Journal of Cancer, 2010
- Randomized Control Trial Comparing Oral Amoxicillin-clavulanate and Ofloxacin With Intravenous Ceftriaxone and Amikacin as Outpatient Therapy in Pediatric Low-risk Febrile NeutropeniaJournal of Pediatric Hematology/Oncology, 2009
- Variation in policies for the management of febrile neutropenia in United Kingdom Children's Cancer Study Group centresArchives of Disease in Childhood, 2007
- Reporting of Noninferiority and Equivalence Randomized TrialsJama-Journal Of The American Medical Association, 2006
- Predicting bacteremia in children with fever and chemotherapy-induced neutropeniaThe Pediatric Infectious Disease Journal, 2004
- Outpatient, sequential, parenteral-oral antibiotic therapy for lower risk febrile neutropenia in children with malignant diseaseCancer, 2003
- Outpatient Management of Febrile Neutropenia in Children with CancerPediatric Drugs, 2003
- Methodology for clinical trials in cancer patients with febrile neutropeniaSupportive Care in Cancer, 1998